STOCK TITAN

Ironwood Pharmaceuticals (NASDAQ: IRON) plans 33,000-share sale via options exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ironwood Pharmaceuticals filed to sell common stock through Morgan Stanley Smith Barney LLC. The filing covers 33,000 shares of common stock with an aggregate market value of $2,527,470.00, expected to be sold on July 13, 2026 on NASDAQ. The shares are tied to an exercise of stock options for cash. The disclosure also notes prior Rule 10b5-1 sales for John Quisel of 34,000 shares of common stock on June 18, 2026 for proceeds of $2,387,296.40.

Positive

  • None.

Negative

  • None.
Shares planned for sale 33,000 shares Common stock to be sold on or about July 13, 2026
Aggregate market value $2,527,470.00 Market value of 33,000 common shares covered by the filing
Prior 10b5-1 sale shares 34,000 shares Common shares sold on June 18, 2026 under 10b5-1 sales for John Quisel
Prior 10b5-1 sale value $2,387,296.40 Proceeds from 34,000-share Rule 10b5-1 sale on June 18, 2026
Planned sale date 07/13/2026 Intended date for sale of 33,000 common shares
Form 144 regulatory
"144: Securities Information Common | Morgan Stanley Smith Barney LLC"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Exercise of Stock Options financial
"Common | 07/13/2026 | Exercise of Stock Options | Issuer"
10b5-1 regulatory
"10b5-1 Sales for JOHN QUISEL 321 Arsenal Street"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stock sale is disclosed for IRON in this Form 144?

The filing covers a planned sale of 33,000 shares of Ironwood Pharmaceuticals common stock, with an aggregate market value of $2,527,470.00, expected to be sold on July 13, 2026 on NASDAQ.

What is the source of the IRON shares to be sold on July 13, 2026?

The 33,000 shares of Ironwood Pharmaceuticals common stock are associated with an exercise of stock options, with the transaction structured for cash settlement on July 13, 2026.

Which broker is handling the planned IRON stock sale?

The planned sale of 33,000 shares of Ironwood Pharmaceuticals common stock is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, based at 1 New York Plaza, New York, NY 10004.

What recent Rule 10b5-1 sales are reported for IRON?

The filing notes Rule 10b5-1 sales for John Quisel of 34,000 shares of Ironwood Pharmaceuticals common stock on June 18, 2026, with total proceeds of $2,387,296.40 from those sales.

On which exchange will the IRON shares be sold under this Form 144?

The 33,000 shares of Ironwood Pharmaceuticals common stock covered by the filing are expected to be sold on the NASDAQ market on or about July 13, 2026.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature